Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BOSTON, Dec. 21, 2020 – Atea Pharmaceuticals (Nasdaq: AVIR) announces that CEO Jean-Pierre Sommadossi will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021, at 9:10 a.m. ET. A live webcast will be available on the company’s website, with a replay for 90 days thereafter.

Atea focuses on developing antiviral therapeutics for severe viral infections including COVID-19, dengue, HCV, and RSV, utilizing a proprietary purine nucleotide prodrug platform.

BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, today announced that Jean-Pierre Sommadossi, Ph.D., Founder, Chairman and Chief Executive Officer of Atea will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 9:10 a.m. ET.

A live webcast of the presentation will be available on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Investors:
Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com

Media:
Carol Guaccero
301-606-4722
contactus@ateapharma.com

FAQ

When will Atea Pharmaceuticals present at the J.P. Morgan Healthcare Conference?

Atea Pharmaceuticals will present on January 11, 2021, at 9:10 a.m. ET.

Where can I watch the Atea Pharmaceuticals presentation?

The presentation will be available via live webcast on Atea's website.

What is Atea Pharmaceuticals focusing on in drug development?

Atea is focused on developing antiviral therapies for life-threatening viral infections, including COVID-19.

What viruses does Atea Pharmaceuticals target?

Atea targets viruses such as SARS-CoV-2, dengue virus, hepatitis C virus, and respiratory syncytial virus.

What is the stock symbol for Atea Pharmaceuticals?

The stock symbol for Atea Pharmaceuticals is AVIR.